PTC (NASDAQ:PTC – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating ...

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been given an average recommendation of “Moderate Buy” ...

Looking back on design software stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including PTC ...

PTC has been in a holding pattern, posting a small loss of 4.7% while floating around $160.81. The stock also fell short of ...

Sometimes, the headline numbers don't tell the whole story. That's definitely the case with industrial software company PTC ...

It has been about a month since the last earnings report for PTC Inc. (PTC). Shares have lost about 6.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Proficio Capital Partners LLC purchased a new position in shares of PTC Inc. (NASDAQ:PTC – Free Report) in the fourth quarter, HoldingsChannel reports. The fund purchased 48,174 shares of the ...

PTC (NasdaqGS:PTC) experienced a 4.52% decline in its total shareholder returns over the past week, coinciding with the appointment of Trac Pham to its Board of Directors. Pham brings a strong record ...

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its target price upped by research analysts at JPMorgan Chase & Co. from $72.00 to $78.00 in a research report issued to clients and investors on ...

Fintel reports that on March 11, 2025, B of A Securities upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from Underperform to Neutral. As of March 5, 2025, the average one-year price ...

Calumet (NASDAQ:CLMT) +10.2% in Monday's trading as UBS raised the maker of hydrocarbon products to Neutral from Sell with a ...